Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients

Authors


Manisha Patel, MD, MSc, 1600 Clifton Rd., MS C-25, Atlanta, GA 30312, USA
Tel.: +1 404 639 2422
Fax: +1 404 718 2119
E-mail: dvn4@cdc.gov
Betsy C. Herold, MD, 1300 Morris Park Ave., Forchheimer 702d, Bronx, NY 10461, USA
Tel.: +1 718 430 2974
Fax: +1 718 430 8627
E-mail: betsy.herold@einstein.yu.edu

Abstract

Patel M, Stefanidou M, Long CB, Fazzari MJ, Tesfa L, Del Rio M, Lamour J, Ricafort R, Madan RP, Herold BC. Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients.
Pediatr Transplantation 2012: 16: 18–28. © 2011 John Wiley & Sons A/S.

Abstract:  CMI responses, combined with quantification of CMV DNA (DNAemia), may identify transplantation recipients at risk for invasive disease. PBMC were collected in pediatric transplantation candidates at one, three, and six months post-transplant in 10 subjects (six renal, three cardiac, one stem cell) and at single time points in eight HC and 14 children greater than one yr post-transplant (LTTx). Cells were stimulated with anti-CD3mAb or CMV pp65 peptide pools and responses assessed by IFNG enzyme-linked immunosorbent spot assay and cytokine secretion. IFNG responses to anti-CD3mAb were significantly lower pretransplant relative to HC and were further decreased at one and three months post-transplant, but recovered to levels comparable to HC by six months. Responses to pp65 among CMV-seropositive recipients followed a similar pattern but recovered by three months. CMV-seropositive LTTx and HC showed a Th1 cytokine response to pp65 stimulation. Three LTTx subjects developed CMV DNAemia; two demonstrated decreased responses to anti-CD3mAB (and pp65 in the CMV seropositive subject) at the onset of DNAemia, which recovered as DNAemia resolved. Monitoring CMI in children is feasible and may provide an adjunct biomarker to predict CMV progression and recovery.

Ancillary